After earning her medical degree from Wayne State University in Michigan, Dr. Coleman completed her ophthalmology residency at the prestigious Long Island Jewish Medical Center. She served as chief resident in her final year. Dr. Coleman then received advanced training at the renowned University of Texas Southwestern Medical Center, where she completed fellowship training in treating glaucoma.
Before arriving at Outlook Eyecare in 2009, Dr. Coleman was head of glaucoma treatmentat a large practice in Philadelphia, where she also was a clinical instructor for residents at Wills Eye Institute.
In her answers, Dr. Coleman talks about what led her to become an ophthalmologist and discusses current research that could lead to a glaucoma cure.
During medical school, I choose an ophthalmology elective course and fell in love with it. I love the combination of surgery and patient care in the office. I tend to be a detail-oriented person, and I found that ophthalmology fit well with that part of my personality.
An exciting development in the treatment of glaucoma is placing an extremely tiny stent — it’s about 1 millimeter long — during cataract surgery. The device is called iStent®, and it’s an excellent treatment option for patients who are managing glaucoma with eye drops. Glaucoma creates pressure behind the eye that can damage the optic nerve and affect a patient’s vision. The iStent helps maintain low pressure after cataract surgery and can lead to some patients discontinuing the use of eye drops.
The most significant advance in my career has been the use of anti-VEGF injections to treat wet macular degeneration. The most common of these drugs is Lucentis, which helps prevent abnormal blood vessel growth and leakage. Before the development of this technology, no good treatment existed for wet macular degeneration, and patients faced the prospect of losing most of their functional vision. At Outlook Eyecare, Dr. Grabowski is our retinal specialist, and he’s able to help maintain and, in some cases, even improve the vision of a patient with wet macular degeneration.
In the field of glaucoma, specifically, researchers today are studying nerve tissue regeneration. What does that mean? When we have the ability to regenerate nerve tissue in the future, we will essentially have a cure for glaucoma, and the devastating vision loss from this disease will be reversible.
I grew up in Cherry Hill, so the opportunity to join Outlook Eyecare was sort of a homecoming. I’m now married with twins — a boy and a girl. I enjoy playing with the kids in my free time and look forward to family ski trips in the near future. I enjoy running, taking exercise classes, and, yes, downhill skiing.
If you are looking for a New Jersey eye doctor, we welcome you to visit us in person, request a consultation using our online form, or call us at (609) 409-2777 (Monroe Township) or (609) 419-1920 (Princeton) . One of our helpful staff members will schedule your appointment with Dr. Coleman or one of our other outstanding eye care professionals.
2019 Outlook Eyecare © All rights reserved.